3Lindholm A, Kahan BD. Inflience of cyclosporine phamacokinetics,trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther, 1993,55:205.
4Gabriel MD.肾移植手册.第3版,北京:人民卫生出版社,2001.
二级参考文献5
1Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation[J]. Clin pharmacol Ther, 1993,55;205.
2Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration - time curve[J]. Translantation, 1999,68; 55.
3Johnston A, David OJ, Cooney GF. Pharmacokinetic validation of Neoral absorption profiling[J]. Transplant Proc, 2000, 32(3): 53.
4Bjom N, Edward C, Gary L, et al. Clinical validation studies of Neoral C2 monitoring: a review[J]. Transplantation, 2002,73(9): 3.
5Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo [J ]. Transplantation, 1999, 68:1356.
7Yoon YS, Bang BK ,Jin DC, et al. Factors influencing long-term outcome of living-donor kidney transplantation in the eyelosporine era [ J]. Clin Transpl, 1992:257-66.
8[1]Pascual M,Theruvath T,Kawai T,et al.Strategies to improve long-term outcomes after renal transplantation[J].N Engl J Med,2002,346(8):580-584.
9[2]Klein IH,Abrahams A,van Ede T,et al.Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects[J].Transp Lantation,2002,73(5):732.
